Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,
Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Viudez A
Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,
Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Blanco C, Crespo E, Gamo M, Villalobos L, Escribano P,
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,
Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,
#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Crespo G, Jimenez-Fonseca P, Custodio A, Lopez C, Carmona-Bayonas A,
Keywords: capecitabine, temozolomide,